Union Bancaire Privee UBP SA Acquires 20,053 Shares of Pfizer Inc. (NYSE:PFE)

Union Bancaire Privee UBP SA raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 12.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 185,982 shares of the biopharmaceutical company's stock after acquiring an additional 20,053 shares during the quarter. Union Bancaire Privee UBP SA's holdings in Pfizer were worth $4,430,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in PFE. Mcdonald Partners LLC raised its position in Pfizer by 9.9% in the 4th quarter. Mcdonald Partners LLC now owns 110,296 shares of the biopharmaceutical company's stock worth $2,926,000 after purchasing an additional 9,963 shares during the period. Bank of Jackson Hole Trust purchased a new stake in shares of Pfizer in the fourth quarter worth $264,000. Harvey Capital Management Inc. bought a new stake in shares of Pfizer in the 4th quarter worth $544,000. ING Groep NV lifted its stake in shares of Pfizer by 48.6% in the 4th quarter. ING Groep NV now owns 1,013,230 shares of the biopharmaceutical company's stock worth $26,881,000 after purchasing an additional 331,403 shares during the period. Finally, Strategic Financial Concepts LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $2,281,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.5%

NYSE PFE traded up $0.37 during trading hours on Thursday, hitting $24.85. The company's stock had a trading volume of 42,445,910 shares, compared to its average volume of 41,112,573. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company's 50-day simple moving average is $22.96 and its two-hundred day simple moving average is $24.98. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $141.28 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.92%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio (DPR) is currently 124.64%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reissued a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Finally, UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.